Trial reportJournal of urban health : bulletin of the New York Academy of Medicine2010
Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.
Trial report in Journal of urban health : bulletin of the New York Academy of Medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00786396 (Directly Observed Therapy for Community-Released HIV+ Prisoners), which is not on this map. Cited by 88 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Directly Observed Therapy for Community-Released HIV+ Prisoners
Who cites it
88 citing papers in PubMed, 9 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- A client-centered relational framework on barriers to the integration of HIV and substance use services: a systematic review.Harm reduction journal · 2019Pooled it
- Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.PLoS medicine · 2019Pooled it
- Integration of care for HIV and opioid use disorder.AIDS (London, England) · 2019Pooled it
- Leveraging the U.S. Criminal Justice System to Access Women for HIV Interventions.AIDS and behavior · 2017Pooled it
- Challenges in the Evaluation of Interventions to Improve Engagement Along the HIV Care Continuum in the United States: A Systematic Review.AIDS and behavior · 2017Pooled it
- The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis.American journal of public health · 2015Pooled it
- A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs.Current HIV/AIDS reports · 2012Pooled it
- Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.Annals of internal medicine · 2012Guideline
- HIV infection and risk of overdose: a systematic review and meta-analysis.AIDS (London, England) · 2012Pooled it
- Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.Journal of substance abuse treatment · 2022Trial
- Act Healthy: A Randomized Clinical Trial Evaluating a Behavioral Activation Intervention to Address Substance Use and Medication Adherence Among Low-Income, Black/African American Individuals Living with HIV/AIDS.AIDS and behavior · 2022Trial
- Retention in clinical trials after prison release: results from a clinical trial with incarcerated men with HIV and opioid dependence in Malaysia.HIV research & clinical practice · 2019Trial
- Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.Drug and alcohol dependence · 2015Trial
- Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.Drug and alcohol dependence · 2015Trial
- Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Contemporary clinical trials · 2014Trial
- An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.Journal of substance abuse treatment · 2014Trial
- Predictors of outcome after short-term stabilization with buprenorphine.Journal of substance abuse treatment · 2013Trial
- Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes.Contemporary clinical trials · 2012Trial
- Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system.Drug and alcohol dependence · 2011Trial
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
HIV-infected prisoners fare poorly after release. Though rarely available, opioid agonist therapy (OAT) may be one way to improve HIV and substance abuse treatment outcomes after release. Of the 69 HIV-infected prisoners enrolled in a randomized controlled trial of directly administered antiretroviral therapy, 48 (70%) met DSM-IV criteria for opioid dependence. Of these, 30 (62.5%) selected OAT, either as methadone (N = 7, 14.5%) or buprenorphine/naloxone (BPN/NLX; N = 23, 48.0%). Twelve-week HIV and substance abuse treatment outcomes are reported as a sub-study for those selecting BPN/NLX. Retention was high: 21 (91%) completed BPN/NLX induction and 17 (74%) remained on BPN/NLX after 12 weeks. Compared with baseline, the proportion with a non-detectable viral load (61% vs 63% log(10) copies/mL) and mean CD4 count (367 vs 344 cells/mL) was unchanged at 12 weeks. Opiate-negative urine testing remained 83% for the 21 who completed induction. Using means from 10-point Likert scales, opioid craving was reduced from 6.0 to 1.8 within 3 days of BPN/NLX induction and satisfaction remained high at 9.5 throughout the 12 weeks. Adverse events were few and mild. BPN/NLX therapy was acceptable, safe and effective for both HIV and opioid treatment outcomes among released HIV-infected prisoners. Future randomized controlled trials are needed to affirm its benefit in this highly vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.